In recent years, cancer immunotherapy targeting PD-1/PD-L1 has shown significant progress in the treatment of various tumors and continues to evolve through ongoing clinical research.[26–28] In this study, we found that the significance of PD-L1 expression in tumor and stromal cells remained inconsistent. Here, CD274 is linked to neoplasm.